09:46:37 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



XenoPort to Present at the Morgan Stanley Global Healthcare Conference

2015-09-04 10:00 ET - News Release


SANTA CLARA, Calif. -- (Business Wire)

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) on Wednesday, September 16, 2015. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and potentially for relapsing forms of multiple sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort has entered into a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under which the NIAAA has initiated a clinical trial evaluating gabapentin enacarbil as a potential treatment for alcohol use disorder, and XenoPort has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior PLC for all indications. XenoPort's pipeline of product candidates also includes a potential treatment for patients with idiopathic Parkinson's disease.

To learn more about XenoPort, please visit the website at www.XenoPort.com.

HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contacts:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

Source: XenoPort, Inc.

© 2024 Canjex Publishing Ltd. All rights reserved.